DE602004032465D1 - Referenzstandard zur charakterisierung von rosuvastatin - Google Patents
Referenzstandard zur charakterisierung von rosuvastatinInfo
- Publication number
- DE602004032465D1 DE602004032465D1 DE602004032465T DE602004032465T DE602004032465D1 DE 602004032465 D1 DE602004032465 D1 DE 602004032465D1 DE 602004032465 T DE602004032465 T DE 602004032465T DE 602004032465 T DE602004032465 T DE 602004032465T DE 602004032465 D1 DE602004032465 D1 DE 602004032465D1
- Authority
- DE
- Germany
- Prior art keywords
- rosuvastatin
- characterization
- reference standard
- standard
- analysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52644903P | 2003-12-02 | 2003-12-02 | |
PCT/US2004/040329 WO2005056534A1 (en) | 2003-12-02 | 2004-12-02 | Reference standard for characterization of rosuvastatin |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004032465D1 true DE602004032465D1 (de) | 2011-06-09 |
Family
ID=34676616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004032465T Active DE602004032465D1 (de) | 2003-12-02 | 2004-12-02 | Referenzstandard zur charakterisierung von rosuvastatin |
Country Status (13)
Country | Link |
---|---|
US (6) | US7244844B2 (de) |
EP (1) | EP1689723B1 (de) |
JP (1) | JP4733047B2 (de) |
KR (1) | KR100887264B1 (de) |
CN (1) | CN1894221B (de) |
AT (1) | ATE507209T1 (de) |
CA (1) | CA2546894C (de) |
DE (1) | DE602004032465D1 (de) |
ES (1) | ES2364143T3 (de) |
IL (1) | IL175511A (de) |
PT (1) | PT1689723E (de) |
TW (1) | TWI351958B (de) |
WO (1) | WO2005056534A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
US7244844B2 (en) * | 2003-12-02 | 2007-07-17 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
US7851624B2 (en) | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
KR101020024B1 (ko) | 2005-02-22 | 2011-03-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법 |
AU2006329006B2 (en) * | 2005-12-20 | 2013-02-28 | Lek Pharmaceuticals D.D. | Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid |
MX2008014552A (es) * | 2007-03-13 | 2009-03-09 | Teva Pharma | Forma de triol de rosuvastatina. |
EP2189456A1 (de) * | 2008-11-14 | 2010-05-26 | LEK Pharmaceuticals d.d. | Neue Omeprazol-Verbindungen |
EP2379506B1 (de) | 2008-12-30 | 2015-09-02 | ArQule, Inc. | Substituierte 5,6-dihydro-6-phenylbenzo[f]-isochinolin-2-aminver-bindungen |
CN103454352B (zh) * | 2013-07-30 | 2015-07-15 | 广东先强药业有限公司 | 一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法 |
CN103776939A (zh) * | 2014-02-11 | 2014-05-07 | 润泽制药(苏州)有限公司 | 瑞舒伐他汀钙制剂有关物质的制备检测方法 |
CN108398501A (zh) * | 2018-03-02 | 2018-08-14 | 海南通用三洋药业有限公司 | 一种检测瑞舒伐他汀钙有关物质的方法 |
CN109020902B (zh) * | 2018-07-23 | 2020-06-02 | 唯智医药科技(北京)有限公司 | 一种瑞舒伐他汀钙杂质及其制备方法与用途 |
CN114280181A (zh) * | 2021-12-23 | 2022-04-05 | 浙江海翔川南药业有限公司 | 一种瑞舒伐他汀中间体及其有关物质的检测方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US37314A (en) * | 1863-01-06 | Improved composition for lemonade | ||
US633198A (en) * | 1899-02-08 | 1899-09-19 | Wilhelm Magnus Hoekerstedt | Automatic-lighting torch. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
ES2110499T3 (es) | 1991-06-19 | 1998-02-16 | Shionogi & Co | Intermediario opticamente activo y su produccion. |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
GB9626746D0 (en) | 1996-12-23 | 1997-02-12 | Knoll Ag | Process |
GB9812413D0 (en) | 1998-06-10 | 1998-08-05 | Glaxo Group Ltd | Compound and its use |
SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
KR20040026705A (ko) | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
SK1402004A3 (sk) | 2001-08-16 | 2005-01-03 | Teva Pharmaceutical Industries Ltd. | Spôsob prípravy vápenatých solí statinov |
SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre demented states |
KR100511533B1 (ko) | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
AR039836A1 (es) | 2002-05-21 | 2005-03-02 | Ranbaxy Lab Ltd | Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
US7566782B2 (en) | 2002-12-10 | 2009-07-28 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
AU2003269478A1 (en) | 2003-08-27 | 2005-03-16 | Hetero Drugs Limited | A novel process for amorphous rosuvastatin calcium |
CN1886383A (zh) | 2003-10-22 | 2006-12-27 | 兰贝克赛实验室有限公司 | 无定形罗苏伐他汀钙的制备方法 |
EP1601658A1 (de) | 2003-11-24 | 2005-12-07 | Teva Pharmaceutical Industries Limited | Kristalline ammoniumsalze von rosuvastatin |
US7244844B2 (en) * | 2003-12-02 | 2007-07-17 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
EP1797046A2 (de) | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Neue verfahren zur herstellung von amorphem rosuvastatincalcium und neue polymorphe form von rosuvastatinnatrium |
JP2008528542A (ja) | 2005-01-31 | 2008-07-31 | チバ ホールディング インコーポレーテッド | ロスバスタチンカルシウム塩の結晶形 |
EP1863773A1 (de) | 2005-03-22 | 2007-12-12 | Unichem Laboratories Limited | Verfahren zur herstellung von rosuvastatin |
US20080161560A1 (en) | 2005-04-04 | 2008-07-03 | Pandurang Balwant Deshpande | Process for Preparation of Calcium Salt of Rosuvastatin |
EP1915349B2 (de) | 2005-06-24 | 2018-09-12 | LEK Pharmaceuticals d.d. | Verfahren zur herstellung von reinem amorphen rosuvastatin-calcium |
WO2006136407A1 (en) | 2005-06-24 | 2006-12-28 | Lek Pharmaceuticals D.D. | Process for preparing amorphous rosuvastatin calcium free of impurities |
GB0514078D0 (en) | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
-
2004
- 2004-12-02 US US11/001,912 patent/US7244844B2/en active Active
- 2004-12-02 ES ES04812772T patent/ES2364143T3/es active Active
- 2004-12-02 JP JP2006541502A patent/JP4733047B2/ja not_active Expired - Fee Related
- 2004-12-02 WO PCT/US2004/040329 patent/WO2005056534A1/en active Application Filing
- 2004-12-02 AT AT04812772T patent/ATE507209T1/de not_active IP Right Cessation
- 2004-12-02 EP EP04812772A patent/EP1689723B1/de not_active Revoked
- 2004-12-02 CA CA002546894A patent/CA2546894C/en not_active Expired - Fee Related
- 2004-12-02 TW TW093137210A patent/TWI351958B/zh not_active IP Right Cessation
- 2004-12-02 KR KR1020067013302A patent/KR100887264B1/ko active IP Right Grant
- 2004-12-02 DE DE602004032465T patent/DE602004032465D1/de active Active
- 2004-12-02 PT PT04812772T patent/PT1689723E/pt unknown
- 2004-12-02 CN CN2004800359220A patent/CN1894221B/zh not_active Expired - Fee Related
-
2006
- 2006-05-09 IL IL175511A patent/IL175511A/en active IP Right Grant
-
2007
- 2007-06-25 US US11/823,045 patent/US7692010B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/823,019 patent/US7692009B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/823,013 patent/US7741482B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/821,968 patent/US7692008B2/en not_active Expired - Fee Related
-
2009
- 2009-01-27 US US12/322,042 patent/US8487097B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7692008B2 (en) | 2010-04-06 |
EP1689723A1 (de) | 2006-08-16 |
US20090188305A1 (en) | 2009-07-30 |
ES2364143T3 (es) | 2011-08-25 |
JP4733047B2 (ja) | 2011-07-27 |
KR100887264B1 (ko) | 2009-03-06 |
US20050187234A1 (en) | 2005-08-25 |
US7244844B2 (en) | 2007-07-17 |
CA2546894A1 (en) | 2005-06-23 |
TW200522959A (en) | 2005-07-16 |
US20070249830A1 (en) | 2007-10-25 |
CA2546894C (en) | 2009-09-08 |
IL175511A (en) | 2011-11-30 |
ATE507209T1 (de) | 2011-05-15 |
CN1894221B (zh) | 2012-08-08 |
PT1689723E (pt) | 2011-07-06 |
US20070249831A1 (en) | 2007-10-25 |
KR20060098396A (ko) | 2006-09-18 |
EP1689723B1 (de) | 2011-04-27 |
US7692010B2 (en) | 2010-04-06 |
TWI351958B (en) | 2011-11-11 |
US7692009B2 (en) | 2010-04-06 |
US20070255059A1 (en) | 2007-11-01 |
JP2007512354A (ja) | 2007-05-17 |
US7741482B2 (en) | 2010-06-22 |
IL175511A0 (en) | 2006-09-05 |
US20070244321A1 (en) | 2007-10-18 |
CN1894221A (zh) | 2007-01-10 |
US8487097B2 (en) | 2013-07-16 |
WO2005056534A1 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175511A0 (en) | Reference standard for characterization of rosuvastatin | |
ATE269295T1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
DE60007095D1 (de) | Calanolide zur hemmung von btk | |
ATE335722T1 (de) | Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
DE60301922D1 (de) | Vorrichtung zur Entnahme von Objekten | |
ATE307618T1 (de) | Vorrichtung zur abgabe von flüchtigen stoffen | |
DE50209307D1 (de) | Vorrichtung zur fussbekleidung | |
EP1700120A4 (de) | Marker für neuromyelitis optica | |
MA28985B1 (fr) | Analogues de loxapine et methodes d'utilisation | |
DE60318831D1 (de) | System zur abgabe von anästhetika | |
DE602004025507D1 (de) | Vanillin-polymere zwecks verwendung zur verdunklung der haut | |
EA200500064A1 (ru) | Многофункциональные маркеры продуктов и способы их получения и применения | |
DE60300407D1 (de) | Vorrichtung zur Impedanzmessung lebender Körper | |
IL173929A0 (en) | Analogues of kahalalide f and pharmaceutical compositions containing the same | |
ECSP045466A (es) | Inhibidores de la peptido-desformilasa | |
DE502004011765D1 (de) | Implantat zur Spreizung der Nasenflügel | |
UY27192A1 (es) | Inhibidores de peptido-deformilasa | |
SE0301650D0 (sv) | Novel compounds | |
DE60333196D1 (de) | Atemerfrischer und mundpflegeprodukt unter verwendung von kardamom l | |
DE60234250D1 (de) | Vorrichtung zur Zell- bzw. Gewebezüchtung | |
AU2003223634A1 (en) | Peptide deformylase inhibitors | |
BR0316544A (pt) | Compostos calcilìticos | |
DE60200296D1 (de) | Gerät zur Detektion von Vorsatzlöchern | |
AU2003304490A1 (en) | Peptide deformylase inhibitors |